Citations

Clear

127 citation(s) found for "Shari, G".

Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
Manrique, Irene , Campbell, Timothy , Kazanecki, Christian C. , Martin, Nathan , Kaiser, Shari M. , Anderson, Larry D. , Lin, Yi , Munshi, Nikhil C. , Anderson, Larry D , Paiva, Bruno , Rytlewski, Julie , Berdeja, Jesús G. , Lonial, Sagar , Raje, Noopur , Moreau, Philippe , Miguel, Jesús F. San

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2104-2105

10.1182/blood-2022-166658 Get It

RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study
Pederson, Holly J. , Pruthi, Sandhya , Goldfarb, Shari, Faubion, Stephanie S.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 21, 2022 | Volume: 115 | Issue: 2 | Pages: 220-221

10.1093/jnci/djac211 | PMID 36409007 Get It

Patient Use of Physicians’ First (Given) Name in Direct Patient Electronic Messaging
Harvey, Jamison A. , Butterfield, Richard , Ochoa, Shari A. , Yang, Yul W.

Mayo Clinic

JAMA Network Open | October 5, 2022 | Volume: 5 | Issue: 10 | Pages: e2234880

10.1001/jamanetworkopen.2022.34880 | PMID 36197668 Get It

This cohort study examines factors that may contribute to whether patients address physicians differently through electronic messaging
Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors
Sella, Tal , Tan‐Wasielewski, Zhenying, Rosenberg, Shoshana M. , Poorvu, Philip D. , Tayob, Nabihah , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Ligibel, Jennifer A. , Rosenberg, Shoshana , Ruddy, Kathryn J , Schapira, Lidia , Partridge, Ann H , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Cancer | July 1, 2022 | Volume: 128 | Issue: 17 | Pages: 3158-3169

10.1002/cncr.34342 | PMID 35775874 Get It

BackgroundWeight gain after a breast cancer diagnosis is common and is associated with inferior outcomes. Young survivors may be especially susceptible to weight changes given the impact of treatment on menopausal status.MethodsThe authors identified women who were diagnosed with stage 0 to III breast cancer at age 40 years or younger between 2006 and 2016 from a multicenter prospective cohort. Self‐reported weight was collected at diagnosis and at 1 year and 3 years postdiagnosis. Tumor and treatment data were obtained from medical records and patient surveys. Multinomial logistic regression was used to identify the factors associated with weight gain (≥5%) or weight loss (≥5%) versus stable weight at 1 year and 3 years postdiagnosis.ResultsThe cohort included 956 women with a median age of 37 years at diagnosis. Mean weight significantly increased over time from 66.54 ± 14.85 kg at baseline to 67.33 ± 15.53 and 67.77 ± 14.65 kg at 1 year and 3 years, respectively (p ≤ .001 for both comparisons). The proportion of women experiencing ≥5% weight gain increased from 24.8% at 1 year to 33.9% at 3 years. At 1 year, less self‐perceived financial comfort, Black race, and stage III disease were significantly associated with weight gain; at 3 years, only less self‐perceived financial comfort remained significant. Baseline overweight or obesity was significantly associated with weight loss at both time points. Chemotherapy, endocrine therapy, and treatment‐related menopause were not associated with weight change.ConclusionsOne third of young breast cancer survivors experienced clinically significant weight gain 3 years after diagnosis; however, treatment‐related associations were not observed. Age‐appropriate lifestyle interventions, including the reduction of financial barriers, are needed to prevent weight gain in this high‐risk population.
Abstract PD13-10: Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
Sella, Tal , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Peppercorn, Jeffrey , Schapira, Lidia , Borges, Virgina F, Come, Steven E. , Zheng, Yue , Tamimi, Rulla M. , Carey, Lisa A. , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: PD13-10-PD13-10

10.1158/1538-7445.sabcs21-pd13-10 Get It

Abstract Background: Extended adjuvant endocrine therapy (eET) beyond the first 5 years of ET improves long-term outcomes in breast cancer survivors. For women who remain premenopausal, evidence for benefit has only been demonstrated to date for 5 years of additional tamoxifen, after an initial 5 years of tamoxifen (from ATLAS, aTTom). There are no data available for eET among premenopausal women treated with initial adjuvant aromatase inhibition (AI) and ovarian functions suppression (OFS). Thus, there is uncertainty regarding the optimal eET regimen for young breast cancer survivors. Methods: The Young Women’s Breast Cancer Study (YWS) is a multicenter prospective cohort of women age ≤40 years newly diagnosed with breast cancer between 2006-2016. Women with stage I-III hormone receptor positive breast cancer, ≥6 years post-diagnosis without breast cancer recurrence were considered candidates for eET. Use of eET was elicited on surveys completed at 6, 7 and/or 8 years post-diagnosis, censoring for recurrence or death. Those completing ≥1 survey were eligible for analysis. Patient characteristics were compared by Chi-square test between eET users and non-users, and logistic regression applied to identify factors associated with eET use. Results: Of 667 potential eET candidates, 73.9% (493/667) returned ≥1 survey between year 6-8 and were eligible for analysis. Compared to those without a year 6-8 survey, the analytic cohort tended to be more non-Hispanic white (86.0% v. 77.6%), more financially comfortable (53.9% v. 39.5%) and more likely to have children pre-diagnosis (59.6% v. 41.4%); age and disease characteristics were similar. Overall, 59.6% (294/493) reported any eET use, with use declining over time from 56.9% (265/466) to 51.4% (219/426) to 46.8% (162/346) at years 6, 7 and 8 post-diagnosis, respectively. Among eET users (n=294), tamoxifen monotherapy was the most common approach (76.9%, 226/294), followed by AI monotherapy (22.1%, 65/294, presumably women who transitioned into menopause), AI-OFS (7.1%, 21/294) and tamoxifen-OFS (3.1%, 9/294). Women diagnosed after 2012 were as likely to receive eET as those diagnosed 2006-2011 (59.4%, 117/197 v. 59.8%, 177/296 p=0.928), however eET more often included AI, with or without OFS (41.0% v. 18.6%, p<0.001), or OFS (17.9% v. 7.3%, p=0.005) in later years. In multivariable analysis, increasing age (per year odds ratio [OR]: 1.10, 95% confidence interval [CI]: 1.04-1.15, p<0.001), higher stage (II v. I: OR: 2.85, 95% CI: 1.81-4.48, p<0.001; III v. I: OR: 3.73, 95% CI: 1.87-7.42, p<0.001) and receipt of chemotherapy (OR: 3.50, 95% CI: 2.08-5.91, p<0.001) were independently significantly associated with any eET use, while women not of white non-Hispanic race/ethnicity were less likely to report eET use (OR: 0.49, 95% CI: 0.28-0.87, p=0.014). Rates of pregnancy in years 1-5 did not differ between eET users and non-users (10.0%, 29/291 v. 8.7%, 17/195, p=0.645) Conclusion: The majority of eligible young breast cancer survivors in the YWS have received eET despite limited data regarding its utility in this population. Heterogeneity exists regarding strategies utilized, and while some factors associated with eET use appear to reflect appropriate risk-based care, such as stage and receipt of chemotherapy, others, including age and race, suggest disparate uptake. Clinical studies are needed in order to determine the optimal approach to eET for young women with a history of early stage hormone receptor-positive breast cancer who remain premenopausal following 5 years of ET. Ensuring risk and preference-based uptake of eET should be a priority. Citation Format: Tal Sella, Yue Zheng, Shoshana M Rosenberg, Kathryn J Ruddy, Shari I Gelber, Rulla M Tamimi, Jeffrey M Peppercorn, Lidia Schapira, Virgina F Borges, Steven E Come, Lisa A Carey, Eric P Winer, Ann H Partridge. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD13-10.
Social Isolation and Incident Heart Failure Hospitalization in Older Women: Women’s Health Initiative Study Findings
Cené, Crystal W. , Leng, Xiaoyan , Faraz, Khushnood , Allison, Matthew , Breathett, Khadijah , Bird, Chloe E. , Coday, Mace , Corbie‐Smith, Giselle , Foraker, Randi E. , Ijioma, Nkechinyere , Rosal, Milagros C. , Sealy–Jefferson, Shawnita , Shippee, Tetyana , Rossouw, Jacques E. , Ludlam, Shari, McGowan, Joan, Ford, Leslie, Geller, Nancy L. , Prentice, Ross, LaCroix, Andrea Z. , Kooperberg, Charles, Howard, Barbara V. , Jackson, Rebecca D. , Thomson, Cynthia A. , Limacher, Marian C. , Robinson, Jennifer G., Kuller, Lewis, Shumaker, Sally A., Brunner, Robert L. , Bird, Chloe , Foraker, Randi , Ijioma, Nkechinyere N, Kroenke, Candyce H , Ijioma, Nkechi , Breathett, Khadijah , Allison, Matthew A , Anderson, Garnet L. , Manson, JoAnn E. , Stefanick, Marcia L , Wactawski‐Wende, Jean

Mayo Clinic

Journal of the American Heart Association | February 22, 2022 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/jaha.120.022907 | PMID 35189692 Get It

Background The association of social isolation or lack of social network ties in older adults is unknown. This knowledge gap is important since the risk of heart failure (HF) and social isolation increase with age. The study examines whether social isolation is associated with incident HF in older women, and examines depressive symptoms as a potential mediator and age and race and ethnicity as effect modifiers. Methods and Results This study included 44 174 postmenopausal women of diverse race and ethnicity from the WHI (Women's Health Initiative) study who underwent annual assessment for HF adjudication from baseline enrollment (1993–1998) through 2018. We conducted a mediation analysis to examine depressive symptoms as a potential mediator and further examined effect modification by age and race and ethnicity. Incident HF requiring hospitalization was the main outcome. Social isolation was a composite variable based on marital/partner status, religious ties, and community ties. Depressive symptoms were assessed using CES‐D (Center for Epidemiology Studies‐Depression). Over a median follow‐up of 15.0 years, we analyzed data from 36 457 women, and 2364 (6.5%) incident HF cases occurred; 2510 (6.9%) participants were socially isolated. In multivariable analyses adjusted for sociodemographic, behavioral, clinical, and general health/functioning; socially isolated women had a higher risk of incident HF than nonisolated women (HR, 1.23; 95% CI, 1.08–1.41). Adding depressive symptoms in the model did not change this association (HR, 1.22; 95% CI, 1.07–1.40). Neither race and ethnicity nor age moderated the association between social isolation and incident HF. Conclusions Socially isolated older women are at increased risk for developing HF, independent of traditional HF risk factors. Registration URL: http://www.clinicaltrials.gov ; Unique identifier: NCT00000611.
Symptoms COVID 19 Positive Vapers Compared to COVID 19 Positive Non-vapers
McFadden, David D., Bornstein, Shari L. , Vassallo, Robert , Salonen, Bradley R. , Bhuiyan, Mohammed Nadir , Schroeder, Darrell R. , Croghan, Ivana T. , Bhuiyan, M Nadir , Vassallo, Robert , Schroeder, Darrell

Mayo Clinic

Journal of Primary Care & Community Health | January 6, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319211062672 | PMID 34986700 Get It

Objectives: The purpose of the present study was to assess and describe the severity of symptoms reported by Covid-19 positive patients who vaped (smoked e-cigarettes) when compared to those who did not vape or smoke at the time of the diagnosis of Covid-19. Methods: Patients from this study are from a well-characterized patient cohort collected at Mayo Clinic between March 1, 2020 and February 28, 2021; with confirmed COVID-19 diagnosis defined as a positive result on reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays from nasopharyngeal swab specimens. Among the 1734 eligible patients, 289 patients reported current vaping. The cohort of vapers (N = 289) was age and gender matched to 1445 covid-19 positive patients who did not vape. The data analyzed included: date of birth, gender, ethnicity, race, marital status, as well as lifestyle history such as vaping and smoking and reported covid-19 symptoms experienced. Results: A logistic regression analysis was performed separately for each symptom using generalized estimating equations (GEE) with robust variance estimates in order to account for the 1:5 age, sex, and race matched set study design. Patients who vaped and developed Covid-19 infection were more likely to have chest pain or tightness (16% vs 10%, vapers vs non vapers, P = .005), chills (25% vs 19%, vapers vs non vapers, P = .0016), myalgia (39% vs 32%, vapers vs non vapers, P = .004), headaches (49% vs 41% vapers vs non vapers, P = .026), anosmia/dysgeusia (37% vs 30%, vapers vs non vapers, P = .009), nausea/vomiting/abdominal pain (16% vs 10%, vapers vs non vapers, P = .003), diarrhea (16% vs 10%, vapers vs non vapers, P = .004), and non-severe light-headedness (16% vs 9%, vapers vs non vapers, P < .001). Conclusion: Vapers experience higher frequency of covid-19 related symptoms when compared with age and gender matched non-vapers. Further work should examine the impact vaping has on post-covid symptom experience.
The role research gap years play in a successful dermatology match
Costello, Collin M. , Harvey, Jamison A. , Besch‐Stokes, Jake , Bhullar, Puneet , Lim, Elisabeth S. , Tollefson, Megha M. , Tolaymat, Leila , Ochoa, Shari A. , Besch-Stokes, J G , Kunze, Katie L. , Costello, Collin M

Mayo Clinic

International Journal of Dermatology | October 31, 2021 | Volume: 61 | Issue: 2 | Pages: 226-230

10.1111/ijd.15964 | PMID 34719024 Get It

AbstractBackgroundA new trend includes taking a dedicated year away from medical school to complete a research fellowship. There is minimal data on the benefit of a gap year. We aimed to identify if a gap year makes a dermatology applicant more successful in The Match.MethodsDermatology applicants who applied to Mayo Clinic Arizona for the 2018–2019 application cycle and Mayo Clinic Rochester, Arizona, and Florida for the 2019–2020 application cycle were surveyed.ResultsIn total, 291 dermatology applicants completed the initial survey, and 236 completed the follow‐up survey. Ninety applicants took a gap year, 198 applicants did not. There was no significant difference in match rates. When comparing match rates at top dermatology residency programs, 40.6% of gap‐year applicants matched to these residencies versus 19.0% of no gap‐year applicants (P < 0.01).ConclusionApplicants should weigh the opportunity costs before pursuing research gap years as they may not be universally helpful. Applicants who want to match at a top dermatology program may benefit from a research gap year. This data may have limited generalizability outside of the United States.
Maternal Monocytes Respond to Cell-Free Fetal DNA and Initiate Key Processes of Human Parturition
Kazemi, Nazanin Yeganeh , Fedyshyn, Bohdana , Sutor, Shari L., Fedyshyn, Yaroslav , Markovic, Svetomir N. , Enninga, Elizabeth Ann L. , Yeganeh Kazemi, Nazanin , Sutor, Shari, Markovic, Svetomir , Enninga, Elizabeth Ann L

Mayo Clinic

The Journal of Immunology | October 18, 2021 | Volume: 207 | Issue: 10 | Pages: 2433-2444

10.4049/jimmunol.2100649 | PMID 34663619 Get It

Abstract Throughout gestation, the maternal immune system is tightly modulated to allow growth of a semiallogeneic fetus. During the third trimester, the maternal immune system shifts to a proinflammatory phenotype in preparation for labor. What induces this shift remains unclear. Cell-free fetal DNA (cffDNA) is shed by the placenta and enters maternal circulation throughout pregnancy. Levels of cffDNA are increased as gestation progresses and peak before labor, coinciding with a shift to proinflammatory maternal immunity. Furthermore, cffDNA is abnormally elevated in plasma from women with complications of pregnancy, including preterm labor. Given the changes in maternal immunity at the end of pregnancy and the role of sterile inflammation in the pathophysiology of spontaneous preterm birth, we hypothesized that cffDNA can act as a damage-associated molecular pattern inducing an inflammatory cytokine response that promotes hallmarks of parturition. To test this hypothesis, we stimulated human maternal leukocytes with cffDNA from primary term cytotrophoblasts or maternal plasma and observed significant IL-1β and CXCL10 secretion, which coincides with phosphorylation of IFN regulatory factor 3 and caspase-1 cleavage. We then show that human maternal monocytes are crucial for the immune response to cffDNA and can activate bystander T cells to secrete proinflammatory IFN-γ and granzyme B. Lastly, we find that the monocyte response to cffDNA leads to vascular endothelium activation, induction of myometrial contractility, and PGE2 release in vitro. Our results suggest that the immune response to cffDNA can promote key features of the parturition cascade, which has physiologic consequences relevant to the timing of labor.
Trajectories of fear of cancer recurrence in young breast cancer survivors
Schapira, Lidia , Gelber, Shari , Poorvu, Philip D. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Come, Steven E. , Partridge, Ann H. , Rosenberg, Shoshana M. , Ruddy, Kathryn J , Partridge, Ann H , Rosenberg, Shoshana , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F.

Mayo Clinic

Cancer | October 8, 2021 | Volume: 128 | Issue: 2 | Pages: 335-343

10.1002/cncr.33921 | PMID 34614212 Get It

Background Fear of cancer recurrence (FCR) is more intense in younger women. Because FCR is a powerful determinant of quality of life, identifying those at risk for persistently elevated FCR can inform timing of interventions. Methods A total of 965 women with stage 0 to stage III breast cancer enrolled in the Young Women's Breast Cancer Study, a prospective cohort of women diagnosed with breast cancer at age ≤40 years, completed the 3‐item Lasry Fear of Recurrence Index. Group‐based trajectory modeling was used to classify distinct FCR patterns from baseline through 5 years post‐diagnosis. Multinomial logistic regression was used to identify patient, disease, and treatment characteristics associated with each trajectory. Results Five FCR trajectories were identified with the majority of participants having moderate (33.1%) or high FCR (27.6%) that improved over time. A total of 6.9% participants had moderate FCR that worsened, whereas 21.7% had high FCR at baseline that remained high throughout. In the fully adjusted multinomial model, stages II and III (vs stage I) were associated with higher odds of being in the high/stable trajectory, whereas stage 0 (vs I), being financially comfortable (vs not comfortable), was associated with lower odds of being in the high/stable trajectory. White (vs non‐White) was associated with higher odds of being in a trajectory that improved over time. Conclusions Although FCR improves over time for many young women with breast cancer, approximately one‐third had FCR that was severe and did not improve or worsened over 5 years after diagnosis. Ongoing monitoring is warranted, with early referral to mental health professionals indicated for those at highest risk for unresolved FCR. Lay Summary Fear of recurrence is common among young women with breast cancer. The authors followed a large cohort of young women diagnosed with breast cancer when they were 40 years of age and younger, and found 5 distinct trajectories that show moderate and severe fears do not always improve over time and may require targeted mental health intervention.